J. Straub

发表

Prognosis of stage II and III colon cancer treated with adjuvant 5-fl uorouracil or FOLFIRI in relation to microsatellite status : results of the PETACC-3 trial †

C. Bokemeyer, J. Tabernero, B. Melichar, 2014 .

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

P. Paik, S. Matsumoto, Hiroshi Tanaka, 2021, Japanese journal of clinical oncology.

Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors

W. Bodmer, R. Poulsom, M. Ilyas, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer

K. Miller, M. Hussain, S. Le Moulec, 2016, Clinical Cancer Research.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

R. Stupp, M. Weller, T. Gorlia, 2016, Oncotarget.

Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06

Jie Yang, N. Reinmuth, E. Smit, 2018, The New England journal of medicine.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

M. Gilbert, R. Stupp, M. Weller, 2018, Clinical Cancer Research.

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

M. Delorenzi, M. Hegi, M. Hamou, 2008, The Journal of molecular diagnostics : JMD.

Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression.

W. Bodmer, J. Efstathiou, M. Ilyas, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Genetic pathways in colorectal and other cancers.

W. Bodmer, M. Ilyas, I. Tomlinson, 1999, European journal of cancer.

Alkaline-mediated differential interaction (AMDI): A simple automatable single-nucleotide polymorphism assay

W. Bodmer, J. Straub, S. Bartlett, 2001, Proceedings of the National Academy of Sciences of the United States of America.

APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits".

J Straub, W F Bodmer, J. Straub, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.

L. de Leval, H. Nicolas, D. Waltregny, 2010, European urology.

Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice.

W. Bodmer, I. Tomlinson, M. Ilyas, 2002, Cancer research.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015 .

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

K. Rau, Tae-You Kim, Joong-Won Park, 2021, British Journal of Cancer.

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

E. Raymond, A. Fasolo, E. Assenat, 2021, British Journal of Cancer.

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC).

J. Kim, K. Rau, C. Yen, 2018, Annals of Oncology.

Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.

N. Reinmuth, P. Paik, E. Felip, 2020 .

Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study

N. Reinmuth, P. Paik, E. Felip, 2019, Annals of Oncology.

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib.

A. Fasolo, E. Assenat, S. Faivre, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Y. Wu, A. Johne, J. Straub, 2019, Annals of Oncology.

Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress.

P. Paik, E. Felip, H. Sakai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Jie Yang, N. Reinmuth, E. Smit, 2020, The New England journal of medicine.

Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression.

W. Bodmer, J. Efstathiou, M. Ilyas, 1999, Proceedings of the National Academy of Sciences of the United States of America.